LONG-TERM SAFETY, TOLERABILITY AND EFFICACY OF RISPERIDONE LONG-ACTING INJECTABLE AND ORAL ATYPICAL ANTIPSYCHOTICS IN SCHIZOPHRENIC PATIENTS: TWO YEAR NATURALISTIC STUDY

被引：0
|
作者：
Lbach, Bernd [1 ]
Rabinowitz, Jonathan [2 ]
Schreiner, Andreas [3 ]
Hargarter, Ludger [4 ]
Diekamp, Bettina [4 ]
机构：
[1] Psychiatr Dienste Thurgau, Munsterlingen, Switzerland
[2] Bar Ilan Univ, Ramat Gan, Israel
[3] Janssen Cilag Beerse, Med Affairs EMEA, Beerse, Belgium
[4] Janssen Cilag GmbH, Neuss, Germany
来源：
SCHIZOPHRENIA RESEARCH | 2010年 / 117卷 / 2-3期
关键词：
D O I：
10.1016/j.schres.2010.02.1015
中图分类号：
R749 [精神病学];
学科分类号：
100205 ;
摘要：
引用
收藏
页码：527 / 527
页数：1
相关论文
共 50 条
  • [1] LONG-TERM SAFETY, TOLERABILITY AND EFFICACY OF RISPERIDONE LONG-ACTING INJECTABLE AND ORAL ATYPICAL ANTIPSYCHOTICS IN SCHIZOPHRENIC PATIENTS: TWO YEAR NATURALISTIC STUDY
    Ibach, B.
    Rabinowitz, J.
    Schreiner, A.
    Hargarter, L.
    Diekamp, B.
    [J]. EUROPEAN PSYCHIATRY, 2010, 25
  • [2] EFFECTIVENESS, TOLERABILITY AND COMPLIANCE OF SCHIZOPHRENIC PATIENTS UNDER TREATMENT WITH ORAL ATYPICAL ANTIPSYCHOTICS OR LONG-ACTING INJECTABLE RISPERIDONE IN DAILY ROUTINE
    Schreiner, A.
    Ibach, B.
    Hargarter, L.
    Diekamp, B.
    [J]. EUROPEAN PSYCHIATRY, 2010, 25
  • [3] Satisfaction of patients and caregivers with long-acting injectable risperidone and oral atypical antipsychotics
    Han, CS
    Lee, BH
    Kim, YK
    Lee, HJ
    Kim, SH
    Kim, L
    Lee, MS
    Joe, SH
    Ham, BJ
    Jung, IK
    [J]. PRIMARY CARE & COMMUNITY PSYCHIATRY, 2005, 10 (03) : 119 - 124
  • [4] Long-term safety and tolerability of long-acting injectable risperidone in patients with schizophrenia or schizoaffective disorder
    Lindenmayer, Jean-Pierre
    Khan, Akbar
    Eerdekens, Marielle
    Van Hove, Ilse
    Kushner, Stuart
    [J]. EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2007, 17 (02) : 138 - 144
  • [5] Long-acting injectable risperidone: Efficacy and safety of the first long-acting atypical antipsychotic
    Kane, JM
    Eerdekens, M
    Lindenmayer, JP
    Keith, SJ
    Lesem, M
    Karcher, K
    [J]. AMERICAN JOURNAL OF PSYCHIATRY, 2003, 160 (06): : 1125 - 1132
  • [6] Risperidone long-acting injectable improves efficacy and safety in schizophrenic patients after changing from oral risperidone
    Kusters, J
    Glue, P
    Katsafouros, K
    Boon, H
    Medori, R
    Parellada, E
    [J]. EUROPEAN PSYCHIATRY, 2005, 20 : S79 - S79
  • [7] Efficacy and tolerability of long-acting risperidone in patients previously treated with opal atypical antipsychotics
    Schreiner, A
    Moeller, HJ
    [J]. SCHIZOPHRENIA RESEARCH, 2006, 81 : 96 - 97
  • [8] Long-acting, injectable risperidone a direct transition from oral atypical antipsychotics
    Schmauss, M
    Schreiner, A
    [J]. EUROPEAN PSYCHIATRY, 2005, 20 : S76 - S76
  • [9] Long-acting atypical injectable antipsychotics in the treatment of schizophrenia: safety and tolerability review
    Canas, Fernando
    Moeller, Hans-Juergen
    [J]. EXPERT OPINION ON DRUG SAFETY, 2010, 9 (05) : 683 - 697
  • [10] Long-acting injectable risperidone: Efficacy and safety
    Kane, JM
    Eerdekens, M
    Keith, SJ
    Lesem, M
    Karcher, K
    Lindenmayer, JP
    [J]. EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2002, 12 : S325 - S325
12345